Precisely, a VIS832-induced dose-dependent cytolysis of autologous CD138 positive MM cell lines as well as a marked survival benefit in mice treated with VIS832 compared to no therapy after injection of CD138 positive MM cells was reported [29]. This evidence concerns the gene SDC1 and Miyoshi myopathy.